Search

Displaying results 5741 - 5750 of 10000 in total
  1. Drug

    Vanillic acid

    go.drugbank.com/drugs/DB02130
    Experimental

    It is the intermediate product in the two-step bioconversion of ferulic acid to vanillin. (J Biotechnol 1996;50(2-3):107-13).

  2. Drug

    2'-Deoxycytidine-5'-Monophosphate

    go.drugbank.com/drugs/DB03798
    Experimental

    A deoxycytosine nucleotide containing one phosphate group esterified to the deoxyribose moiety in the 2'-,3'- or 5- positions. [PubChem]

  3. Drug

    Jojoba oil

    go.drugbank.com/drugs/DB14252
    Approved

    Jojoba oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  4. Drug

    Scutellaria lateriflora

    go.drugbank.com/drugs/DB14339
    Approved

    Scutellaria lateriflora is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  5. Drug

    Cobitolimod

    go.drugbank.com/drugs/DB14819
    Investigational

    Cobitolimod is under investigation in clinical trial NCT03178669 (The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis).

  6. Drug

    KAHR-102

    go.drugbank.com/drugs/DB17427
    Investigational

    KAHR-102 is a dual signaling protein fusing cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to the Fas-ligand (FasL).

  7. Drug

    HMI-103

    go.drugbank.com/drugs/DB17684
    Investigational

    HMI-102 is an investigational gene therapy designed to encode the phenylalanine-4-hydroxylase (PAH) gene, mutated in people with phenylketonuria.

  8. Drug

    PI-0824

    go.drugbank.com/drugs/DB05516
    Investigational

    The goal of this therapy is to reduce the production of antibodies that cause PV blisters by acting only on the disease causing components of the immune system. … People with PV produce antibodies that attack the cells of the skin, resulting in blisters which, if left untreated, can lead to devastating infections and discomfort.

  9. Drug

    LB-001

    go.drugbank.com/drugs/DB17685
    Experimental

    LB-001 is a gene editing therapy designed to incorporate a functioning version of the faulty methylmalonyl-COA mutase (MUT) gene into the genome of patients with methylmalonic acidemia.

  10. Drug

    Ginisortamab

    go.drugbank.com/drugs/DB18863
    Investigational

    Ginisortamab is under investigation in clinical trial NCT04393298 (A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced